Gene-modified cell therapy (GMCT) is evolving as a major new genre of medicine, offering cures to what are currently considered incurable diseases. Unlike traditional medicines, most GMCTs are made from a patient’s own cells where they are modified with the introduction of new genes. With almost 4 000 new GMTCs being developed in clinical trials around the world, their impact could be comparable to that of antibiotics during the last century. The greatest stumbling block for this therapy is the delivery of new genes into cells.
Indee Labs has developed a microfluidic gene delivery platform that can be used for gentle, scalable, and viral-free delivery of a range of molecules to several cell types, including human primary immune cells. Their microfluidic device uses fluid dynamics to force genetic material into a cell without the risks associated with viral vectors. The application of this microfluidic vortex shedding (µVS) technique has been demonstrated and published in Nature Scientific Reports.
Dr Warren McKenzie, CEO of Indee Labs Australia said, “What we have demonstrated is the only scalable gene-delivery technology for GMCT manufacturing that does not damage cells or their DNA.”